Oncolytic virus (OV) treatment may offer a new treatment option for the aggressive brain tumor glioblastoma. Clinical trials testing oncolytic viruses in this patient group have shown promising results, with patients achieving impressive long-term clinical responses. However, the number of responders to each OV remains low. This is thought to arise from the large heterogeneity of these tumors, both in terms of molecular make-up and their immune-suppressive microenvironment, leading to variability in responses. An approach that may improve response rates is the personalized utilization of oncolytic viruses against Glioblastoma (GBM), based on specific tumor-or pa-tient-related characteristics. In this review, we discuss potential biomarkers for response to different OVs as well as emerging ex vivo assays that in the future may enable selection of optimal OV for a specific patient and design of stratified clinical OV trials for GBM.

, , , ,
doi.org/10.3390/cancers13040614, hdl.handle.net/1765/134566
Cancers
Department of Neurosurgery

Stavrakaki, E. (Eftychia), Dirven, C.M.F, & Lamfers, M.L.M. (2021). Personalizing oncolytic virotherapy for glioblastoma: In search of biomarkers for response. Cancers (Vol. 13, pp. 1–22). doi:10.3390/cancers13040614